78 related articles for article (PubMed ID: 19854533)
1. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.
Kalikaki A; Koutsopoulos A; Hatzidaki D; Trypaki M; Kontopodis E; Stathopoulos E; Mavroudis D; Georgoulias V; Voutsina A
Lung Cancer; 2010 Jul; 69(1):110-5. PubMed ID: 19854533
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic.
Weiss GJ; Ganeshan B; Miles KA; Campbell DH; Cheung PY; Frank S; Korn RL
PLoS One; 2014; 9(7):e100244. PubMed ID: 24987838
[TBL] [Abstract][Full Text] [Related]
3. SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer.
Wang Y; Xue Q; Zheng Q; Jin Y; Shen X; Yang M; Zhou X; Li Y
Lab Invest; 2021 Apr; 101(4):463-476. PubMed ID: 33303972
[TBL] [Abstract][Full Text] [Related]
4. At the Front Line of Opioid Use Disorder.
Nathan N
Anesth Analg; 2023 Sep; 137(3):469. PubMed ID: 37590791
[No Abstract] [Full Text] [Related]
5. Efficacy of platinum-based adjuvant chemotherapy for epidermal growth factor receptor-mutant lung adenocarcinoma.
Onodera K; Yokota I; Matsumura Y; Hayasaka K; Shiono S; Abe J; Notsuda H; Sakurada A; Suzuki H; Okada Y
J Thorac Dis; 2023 Dec; 15(12):6534-6543. PubMed ID: 38249908
[TBL] [Abstract][Full Text] [Related]
6. Association between epidermal growth factor receptor gene mutation status and short-term efficacy of first-line platinum-containing chemotherapy in advanced non-small cell lung cancer.
Chen L; Qi Q; Zhu M; Zhang Y; Peng Y; Liu Y
Biomed Rep; 2022 Jul; 17(1):56. PubMed ID: 35719841
[TBL] [Abstract][Full Text] [Related]
7. Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.
Judd J; Abdel Karim N; Khan H; Naqash AR; Baca Y; Xiu J; VanderWalde AM; Mamdani H; Raez LE; Nagasaka M; Pai SG; Socinski MA; Nieva JJ; Kim C; Wozniak AJ; Ikpeazu C; de Lima Lopes G; Spira AI; Korn WM; Kim ES; Liu SV; Borghaei H
Mol Cancer Ther; 2021 Dec; 20(12):2577-2584. PubMed ID: 34518295
[No Abstract] [Full Text] [Related]
8. Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors.
de Wit M; Gao Y; Mercieca D; de Heer I; Valkenburg B; van Royen ME; Aerts J; Sillevis Smitt P; French P
EBioMedicine; 2020 Jun; 56():102796. PubMed ID: 32512509
[TBL] [Abstract][Full Text] [Related]
9. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
[TBL] [Abstract][Full Text] [Related]
10. A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations.
Lei L; Wang WX; Yu ZY; Liang XB; Pan WW; Chen HF; Wang LP; Fang Y; Wang M; Xu CW; Fang MY
Transl Oncol; 2020 Feb; 13(2):329-335. PubMed ID: 31881505
[TBL] [Abstract][Full Text] [Related]
11.
Ludovini V; Ricciuti B; Tofanetti FR; Mencaroni C; Giannarelli D; Sidoni A; Reda MS; Siggillino A; Baglivo S; Crinò L; Bellezza G; Chiari R; Metro G
Mol Clin Oncol; 2018 Dec; 9(6):689-696. PubMed ID: 30546903
[TBL] [Abstract][Full Text] [Related]
12. A novel RFLP-ARMS TaqMan PCR-based method for detecting the BRAF V600E mutation in melanoma.
Zhang Y; Qu S; Zhao J; Yu T; Guo L; Yin S; Hu X; Chen W; Lai W; Huang J
Oncol Lett; 2018 Aug; 16(2):1615-1621. PubMed ID: 30008844
[TBL] [Abstract][Full Text] [Related]
13. Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.
Aredo JV; Padda SK
Curr Treat Options Oncol; 2018 Jun; 19(8):43. PubMed ID: 29951788
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in patients with skeletal-related events at non-small-cell lung cancer diagnosis.
Tominaga H; Setoguchi T; Shimada H; Nagano S; Sasaki H; Ishidou Y; Sato M; Mizuno K; Inoue H; Komiya S
Mol Clin Oncol; 2017 Nov; 7(5):897-902. PubMed ID: 29181185
[TBL] [Abstract][Full Text] [Related]
15. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with
Arbour KC; Jordan E; Kim HR; Dienstag J; Yu HA; Sanchez-Vega F; Lito P; Berger M; Solit DB; Hellmann M; Kris MG; Rudin CM; Ni A; Arcila M; Ladanyi M; Riely GJ
Clin Cancer Res; 2018 Jan; 24(2):334-340. PubMed ID: 29089357
[No Abstract] [Full Text] [Related]
16. Sensitive genotyping of mutations in the EGFR gene from NSCLC patients using PCR-GoldMag lateral flow device.
Li XY; Zhang C; Zhang QL; Zhu JL; Liu Q; Chen MW; Yang XM; Hui WL; Cui YL
Sci Rep; 2017 Aug; 7(1):8346. PubMed ID: 28827701
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of ABCB1 in stage I lung adenocarcinoma.
Zou F; Seike M; Noro R; Kunugi S; Kubota K; Gemma A
Oncol Lett; 2017 Jul; 14(1):313-321. PubMed ID: 28693170
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features of Chinese lung cancer patients with
Ning H; Liu M; Wang L; Yang Y; Song N; Xu X; Ju J; Jiang G
J Thorac Dis; 2017 Mar; 9(3):796-801. PubMed ID: 28449488
[TBL] [Abstract][Full Text] [Related]
19. K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value.
D'Arcangelo M; Cappuzzo F
ISRN Mol Biol; 2012; 2012():837306. PubMed ID: 27398239
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
